Ophir Gottlieb | Apr 17, 2012 05:38AM ET
Endocyte, Inc. (ECYT) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs), and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, primarily to healthy cells
This is a note that examines order flow -- one of the most misused and over diagnosed trading signals in the options market. Let's take a close look at how option order flow can be protected, hidden, anonymously and electronically negotiated and ultimately, how finding information inside of it is close to impossible when its information is hidden appropriately.
Let's start with the news yesterday:
(Reuters) - Endocyte Inc said Merck & Co Inc had acquired the development and marketing rights of its experimental cancer drug, the latest in the string of licensing deals by the No. 2 U.S. drugmaker to beef up its cancer drug pipeline.
Shares of Endocyte, which had a market capitalization of about $136.18 million before the deal, more than doubled in value to $8.20 in early Monday trade. The stock was the biggest percentage gainer on the Nasdaq.
Endocyte, which is responsible for a majority of the funding and completion of the ovarian cancer trial, will receive $120 million in cash and up to $880 million in milestone payments.
"We also believe that this transaction definitely cracks the door open for an eventual acquisition by Merck, if they like what they see in the next couple of years ...," Cowen and Co analyst Simos Simeonidis said in a note to clients.
Source: Endocyte jumps on plans for cancer drug candidate
OK, so we have the news out of the way... let's focus on order flow and some of the rather fine intricacies. First, let's look to the Options Tab as of today, below.
I can see that the OI in the Apr 5 calls went from 141 to 488 on 3-8-2012, so the OI started to expand based on trades made on 3-7-2012 (OI adjusts the day after). Of course, that OI has gone all the way to 1,666. I've included the Time & Sales Tab from Livevol® Pro for those calls on that day, below.
Let's start with a rather simple illustration, and then move to one of the finer points in option trading. First:
There's a deeper way that option prices are negotiated without a broker, without knowledge of the counter-party and without any verbal correspondence. It's a language that market takers use to communicate with market-makers. Let's look at one of those -- this is in the Apr. 7.5 calls.
Efficient Communication: The market maker(s) knew a buyer was out there, and signaled that a $0.35 sale could be had for small (15 @ $0.35). The market taker wanted to pay $0.30 for size (256 lot). This is a completely anonymous electronic negotiation. Ultimately the $0.30 bid was hit for 244 contracts.
Market Manipulation: A more sinister possibility is that the bid and offer were from the same party. If the buyer is $0.30 bid, but no one will bite, that same party may bring down the bid, lower the offer (for small size), wait a little while, then put a size bid one tick below that offer in hopes that someone hits it, or even more tricky, forces an auto-trade for all the system that are based on a theoretical value that uses mid-market.
In this particular case, I can see the NBBO right before the trade was in fact $0.20 x $0.40. Then the offer was lowered to $0.35. Then a $0.25 bid came in, no action. That bid was dropped, leaving a $0.20 x $0.35 market. The bid was raised to $0.30, and the offer moved to $0.40. Still no action in the bid, the offer was dropped back to $0.35, and finally, the $0.30 bid was hit (110x here, and 134 more right after). I've included the sequence below in actual quotes, which is probably easier to follow.
Ultimately, I do see rather large (relatively) call buyers in the Apr 5 calls before the 3-14-2012 news that held onto the position through today. Now I see some sellers @ $2.70 (offering down from an NBBO right before of $2.65 x $2.90). The Apr 7.5 call opening orders came after the 3-14-2012 news, so that's likely spec rather than any kind of insider knowledge. Order flow may have tipped to some forward looking information in the Apr 5 calls (ya know, or not), but it was hard to read.
This is trade analysis, not a recommendation.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.